Clinical Trial Update: Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker [Phase 2]

View source ↗

Summary

This Phase 2 trial compares hypomethylating agents to intensive chemotherapy in Acute Myeloid Leukemia, using 5hmC as a blood-based minimal residual disease mar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Decitabine (Decitabine)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML) | Phase 2 | Status: NOT_YET_RECRUITING